AstraZeneca acquires Fusion Pharmaceuticals for $2.4bn, expanding its oncology portfolio.
AstraZeneca acquires Fusion Pharmaceuticals for $2.4bn, expanding its oncology portfolio and utilizing Fusion's pipeline of radioconjugates, including its most advanced program for metastatic castration-resistant prostate cancer. This acquisition strengthens AstraZeneca's presence in Canada and supports its focus on oncology. The global radiopharmaceutical market is expected to grow from $7bn in 2022 to $39bn by 2023.
March 19, 2024
25 Articles